Viking Therapeutics VKTX Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $118.12M-28.8% | $165.81M+65.2% | $100.38M+196% | $33.88M-10.7% | $37.94M+42.2% | ||
| $484.85M-10.2% | $539.93M-12.1% | $614.19M-20.6% | $773.84M-4.9% | $813.92M-7.1% | ||
| $1.22M-32.2% | $1.81M-19.4% | $2.24M-20.4% | $2.82M+225% | $865K-23.3% | ||
| $608.21M-15.0% | $715.6M-3.1% | $738.7M-10.7% | $827.02M-4.5% | $866.02M-4.5% | ||
| $0-100% | $85K-87.2% | $666K-14.6% | $780K-12.6% | $892K-11.1% | ||
| $33K-28.3% | $46K0.0% | $46K0.0% | $46K0.0% | $46K0.0% | ||
| $608.24M-15.0% | $715.73M-3.2% | $739.42M-10.7% | $827.85M-4.5% | $866.99M-4.5% | ||
| $67.18M+26.2% | $53.25M+1,107% | $4.41M-19.7% | $5.49M-28.7% | $7.7M-21.5% | ||
| $39.14M+68.1% | $23.28M+9.7% | $21.22M-18.5% | $26.02M+129% | $11.37M-33.5% | ||
| $0-100% | $137K-68.6% | $437K-6.6% | $468K-6.0% | $498K+1.8% | ||
| $106.33M+38.7% | $76.67M+194% | $26.07M-18.5% | $31.98M+63.4% | $19.57M-28.6% | ||
| $0-100% | $137K-81.9% | $755K-14.0% | $878K-12.2% | $1M-10.6% | ||
| $106.33M+38.7% | $76.67M+191% | $26.39M-18.5% | $32.39M+61.3% | $20.08M-28.4% | ||
| $1K0.0% | $1K0.0% | $1K0.0% | $1K0.0% | $1K0.0% | ||
| $1.51B+1.5% | $1.49B+6.0% | $1.4B+0.6% | $1.39B+1.0% | $1.38B+0.9% | ||
| -$1.01B-18.7% | -$847.55M-22.9% | -$689.88M-15.2% | -$599.1M-12.3% | -$533.54M-9.4% | ||
| -$856K-326% | $378K+1.1% | $374K+325% | -$166K+23.1% | -$216K+72.6% | ||
| —— | $0— | $0— | $0— | $0— | ||
| $501.92M-21.5% | $639.06M-10.4% | $713.03M-10.4% | $795.46M-6.1% | $846.92M-3.8% | ||
| $608.24M-15.0% | $715.73M-3.2% | $739.42M-10.7% | $827.85M-4.5% | $866.99M-4.5% | ||
| $484.85M-10.2% | $539.93M-12.1% | $614.19M-20.6% | $773.84M-4.9% | $813.92M-7.1% | ||
| $4.02M-50.1% | $8.05M-63.2% | $21.89M+32.8% | $16.48M+23.9% | $13.3M+283% | ||
| $33K-28.3% | $46K0.0% | $46K0.0% | $46K0.0% | $46K0.0% | ||
| $0-100% | $85K-87.2% | $666K-14.6% | $780K-12.6% | $892K-11.1% | ||
| $0-100% | $85K-87.2% | $666K-14.6% | $780K-12.6% | $892K-11.1% | ||
| $0-100% | $85K-87.2% | $666K-14.6% | $780K-12.6% | $892K-11.1% | ||
| —— | $137K-81.9% | $755K-14.0% | $878K-12.2% | $1M-10.6% | ||
| -$856K-326% | $378K+1.1% | $374K+325% | -$166K+23.1% | -$216K+72.6% | ||
| $1.51B+1.5% | $1.49B+6.0% | $1.4B+0.6% | $1.39B+1.0% | $1.38B+0.9% | ||
| $1K0.0% | $1K0.0% | $1K0.0% | $1K0.0% | $1K0.0% | ||
| $39.14M+68.1% | $23.28M+9.7% | $21.22M-18.5% | $26.02M+129% | $11.37M-33.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Viking Therapeutics cover its short-term obligations?
- Its current ratio is 5.72 — current assets exceed current liabilities.
- Where does Viking Therapeutics's balance sheet data come from?
- Every line is extracted from Viking Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.